Yang et al. demonstrated that the ALDH1A1-RXRα-NEK2 signaling pathway may play a key role in acquired drug resistance and disease relapse in myeloma, suggesting that specific inhibitors of ALDH1A1 are worthy for development of new myeloma treatments [30]. Here, RXRA is linked to plasma cell myeloma.